70 related articles for article (PubMed ID: 7563395)
1. A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.
Scher HI
J Urol; 1995 Nov; 154(5):1970-1. PubMed ID: 7563395
[No Abstract] [Full Text] [Related]
2. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of chemotherapy in advanced urothelial cancer.
Calabrò F; Sternberg CN
Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and carboplatin for advanced breast cancer.
Perez EA; Hartmann LC
Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
[TBL] [Abstract][Full Text] [Related]
7. A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.
Chatelut E; Chevreau C; Brunner V; Martinez M; Houin G; Bugat R; Canal P
Cancer Chemother Pharmacol; 1995; 35(5):391-6. PubMed ID: 7850920
[TBL] [Abstract][Full Text] [Related]
8. Current optimal chemotherapy for advanced urothelial cancer.
Sonpavde G; Galsky MD; Hutson TE
Expert Rev Anticancer Ther; 2008 Jan; 8(1):51-61. PubMed ID: 18095883
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
10. [Organ-preserving treatment of bladder cancer with combined radiochemotherapy: Do patients profit from additional neoadjuvant chemotherapy?].
Diestelhorst A; Dunst J
Strahlenther Onkol; 1999 Aug; 175(8):414-5. PubMed ID: 10481776
[No Abstract] [Full Text] [Related]
11. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
Assikis V; Buzdar A; Yang Y; Smith T; Theriault R; Booser D; Valero V; Walters R; Singletary E; Ames F; Hortobagyi G
Cancer; 2003 Jun; 97(11):2716-23. PubMed ID: 12767083
[TBL] [Abstract][Full Text] [Related]
12. The treatment of advanced gastric cancer.
Wils J
Semin Oncol; 1996 Jun; 23(3):397-406. PubMed ID: 8658224
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
Mikami K; Nakagawa S; Takada H; Ebisui K; Sugimoto K; Watanabe H; Maegawa M; Nakao M
Hinyokika Kiyo; 1994 Apr; 40(4):303-7. PubMed ID: 8191968
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
15. Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.
Tsuchiya N; Inoue T; Narita S; Kumazawa T; Saito M; Obara T; Tsuruta H; Horikawa Y; Yuasa T; Satoh S; Habuchi T
J Urol; 2008 Dec; 180(6):2389-95. PubMed ID: 18930278
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
17. Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy.
Yokomizo A; Yamamoto K; Kinukawa N; Tsunoda T; Koga H; Naito S
Int J Urol; 2007 Jun; 14(6):500-4. PubMed ID: 17593093
[TBL] [Abstract][Full Text] [Related]
18. Is the use of anything but MVAC justified in the evidence-based medicine era?
Ok JH; Cambio A; Lara PN; Evans CP
Curr Opin Urol; 2005 Sep; 15(5):312-4. PubMed ID: 16093854
[No Abstract] [Full Text] [Related]
19. Carboplatin, methotrexate and vinblastin (Carbo-MV) for advanced urothelial cancer. A phase II trial.
Klocker J; Pont J; Schumer J; Prüger J; Kienzer H
Am J Clin Oncol; 1991 Aug; 14(4):328-30. PubMed ID: 1862764
[TBL] [Abstract][Full Text] [Related]
20. Fibromatosis of the neck causing airway obstruction managed effectively with weekly low-dose methotrexate and vinblastine.
Sze H; Yeung MW
Hong Kong Med J; 2009 Jun; 15(3):221-3. PubMed ID: 19494380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
